The news directly pertains to Biomarin Pharmaceutical as Citigroup has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term, although the Neutral rating suggests that the overall outlook for the company remains unchanged.